0000000001231413

AUTHOR

Stefania Candria

showing 1 related works from this author

Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: Recommended schedule for expected activity…

2018

// Gemma Bruera 1, 2 , Silvia Massacese 3 , Stefania Candria 1 , Antonio Galvano 4 , Rosa Manetta 5 , Aldo Victor Giordano 5 , Sergio Carducci 5 , Alessandra Di Sibio 5 , Eugenio Ciacco 3 , Antonio Russo 4 , Enrico Ricevuto 1, 2 and on behalf of Oncology Network ASL1 Abruzzo, Italy 1 Oncology Territorial Care Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L’Aquila, L’Aquila, Italy 2 Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy 3 Pharmacy Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, L’Aquila, Italy 4 Medical Oncology Unit, Department of Surgical, Oncological and Stomatological Sciences, Univers…

0301 basic medicinemedicine.medical_specialtyFOLFIRINOXPhase II studyPhases of clinical research03 medical and health sciences0302 clinical medicineFIr/FOxFIr/FOx; First-line; Metastatic pancreatic ductal adenocarcinoma; Phase II study; Triplet chemotherapyInternal medicinemedicineMucositisPerformance statusbusiness.industryFirst-linemedicine.diseaseGemcitabineOxaliplatinIrinotecan030104 developmental biologyMetastatic pancreatic ductal adenocarcinomaOncology030220 oncology & carcinogenesisLiver functionTriplet chemotherapybusinessResearch Papermedicine.drug
researchProduct